Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


PP-UNP-USA-5796

Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account
We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


​​​​​​​PP-UNP-USA-5796

Order samples

Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


​​​​​​​PP-UNP-USA-5796

Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796

Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading
Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading

PP-UNP-USA-5796

Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Change IndicationLoading
Search
Menu
Close
CIDPAbout PANZYGAEfficacyEfficacyTrial designEfficacySafety and tolerabilityDosingPatient profilesMaterials and supportMaterials and supportEventsMaterialsVideosSupport homePANZYGA Co-Pay ProgramsPfizer IGuideFAQsRequest a representativeIg Companion
Prescribing InformationIndicationsPatient Site

Dosing

The first and only IVIg with 2 FDA-approved maintenance dosing options for CIDP1
  • In the CIDP trial, a loading dose of 2 g/kg of PANZYGA was given followed by 7 maintenance infusions every 3 weeks over a period of 6 months1
  • The initial infusion rate should be maintained for 30 minutes, and if tolerated, the infusion rate may be gradually increased every 15-30 minutes to a maximum of 12 mg/kg/min (0.12 mL/kg/min), as tolerated1
PANZYGA maintenance dosing can be adjusted to 2 g/kg if clinically indicated1 Rescue dosing treatment in clinical trial1-3
Limitations: Response rate in patients receiving rescue dosing was an exploratory endpoint. No statistical conclusions may be drawn.
  • Patients in the 0.5 g/kg and 1 g/kg arms had the option of rescue dosing treatment with 2 consecutive infusions of 2 g/kg at 3-week intervals if clinical criteria were met1
  • Clinical criteria included patients who were stable at week 6 or deteriorated between week 3 and week 182
Example infusion durations for PANZYGARamp-up schedule example for an adult patient with CIDP, as tolerated1
  • The example shown here illustrates a ramp-up schedule for an 80-kg patient using rates of 1, 2, 4, 8, and 12 mg/kg/min
  • PANZYGA should be started at 1 mg/kg/min and continued at the infusion rates stated here, if tolerated
  • For patients at risk of renal dysfunction or thromboembolic events, administer PANZYGA at the minimum infusion rate practicable. Do not exceed 3.3 mg/kg/min (0.033 mL/kg min). Discontinue if renal function deteriorates
Infusion rate calculator
Step 1: Choose indication
With this calculator, you can determine:
  • infusion ramp-up rate to program into an IV infusion pump
  • estimated time to complete the infusion
Choose an indication:
Step 2: Enter the patient’s body weight and PANZYGA dose for this infusion

Adult patient with CIDP

One field from each section below is required.
Enter patient’s body weight
  lb
OR
  kg
ANDEnter patient’s PANZYGA dose for this infusion
   g
OR
  mL
Calculated answer: Recommended ramp-up infusion rates

Adult patient with CIDP

Based on patient’s body weight of {{weight}} and a dose of {{dose}} of PANZYGA, see below for recommended ramp-up infusion rates.

First 30 minutes

0.01 mL/kg/min
(1 mg/kg/min)

{{doseGrams.firstInterval}}

mL/hr

Next 15-30 minutes

(if previous is tolerated)

0.02 mL/kg/min
(2 mg/kg/min)

{{doseGrams.secondInterval}}

mL/hr

Next 15-30 minutes

(if previous is tolerated)

0.04 mL/kg/min
(4 mg/kg/min)

{{doseGrams.thirdInterval}}

mL/hr

Next 15-30 minutes

(if previous is tolerated)

0.08 mL/kg/min
(8 mg/kg/min)

{{doseGrams.fourthInterval}}

mL/hr

Maximum Infusion Rate

(if previous is tolerated)

0.12 mL/kg/min
(12 mg/kg/min)

{{doseGrams.maxInfusion}}

mL/hr

Estimated time to infuse {{dose}} is between {{minInfusionTime}} - {{maxInfusionTime}}

(if the rates above are tolerated by the patient)

Step 2: Enter patient's body weight and PANZYGA dose for this infusion

Patient 2 years or older with PI

One field from each section below is required.
Enter patient’s body weight
  lb
OR
  kg
ANDEnter patient’s PANZYGA dose for this infusion
   g
OR
  mL
Calculated answer: Recommended ramp-up infusion rates

Patient 2 years or older with PI

Based on patient’s body weight of {{weight}} and a dose of {{dose}} of PANZYGA, see below for recommended ramp-up infusion rates.

First 30 minutes

0.01 mL/kg/min
(1 mg/kg/min)

{{doseGrams.firstInterval}}

mL/hr

Next 15-30 minutes

(if previous is tolerated)

0.04 mL/kg/min
(4 mg/kg/min)

{{doseGrams.secondInterval}}

mL/hr

Next 15-30 minutes

(if previous is tolerated)

0.08 mL/kg/min
(8 mg/kg/min)

{{doseGrams.thirdInterval}}

mL/hr

Maximum Infusion Rate

(if previous is tolerated)

0.14 mL/kg/min
(14 mg/kg/min)

{{doseGrams.maxInfusion}}

mL/hr

Estimated time to infuse {{dose}} is between {{minInfusionTime}} - {{maxInfusionTime}}

(if the rates above are tolerated by the patient)

Step 2: Enter the patient’s body weight and PANZYGA dose for this infusion

Adult patient with cITP

One field from each section below is required.

Enter patient’s body weight

  lb
OR
  kg
ANDEnter patient’s PANZYGA dose for this infusion
   g
OR
  mL
Calculated answer: Recommended ramp-up infusion rates

Adult patient with cITP

Based on patient’s body weight of {{weight}} and a dose of {{dose}} of PANZYGA, see below for recommended ramp-up infusion rates.

First 30 minutes

0.01 mL/kg/min
(1 mg/kg/min)

{{doseGrams.firstInterval}}

mL/hr

Next 15-30 minutes

(if previous is tolerated)

0.04 mL/kg/min
(4 mg/kg/min)

{{doseGrams.secondInterval}}

mL/hr

Maximum Infusion Rate

(if previous is tolerated)

0.08 mL/kg/min
(8 mg/kg/min)

{{doseGrams.maxInfusion}}

mL/hr

Estimated time to infuse {{dose}} is between {{minInfusionTime}} - {{maxInfusionTime}}

(if the rates above are tolerated by the patient)

References:References:Panzyga. Prescribing Information. Octapharma USA Inc.; 2025.Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): study design and protocol. J Peripher Nerv Syst. 2018;23:108-114.Cornblath DR, van Doorn PA, Hartung HP, et al; ProCID Investigators. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 2022;145:887-896.
Patient profiles
Discover the different types of patients who may benefit from PANZYGA treatment.
View patient profiles
Loading
Learn more about PANZYGA 
Co-Pay Programs
Loading
Educational materials
Educational materials and resources for HCPs and patients.
Get educational materials and resources
Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PAN-USA-1048
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367

INDICATIONS AND USAGE
PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.
IMPORTANT SAFETY INFORMATIONWARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
  • Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IGIV products, including PANZYGA. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer PANZYGA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Full Prescribing Information, Warnings and Precautions (5.2, 5.4)]
Contraindications
PANZYGA is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.
Warnings and Precautions
Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure.
Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving PANZYGA. 
Aseptic meningitis syndrome may occur in patients receiving PANZYGA, especially with high doses or rapid infusion.Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to PANZYGA treatments. Risk factors for hemolysis include high doses and non-O-blood group. Closely monitor patients for hemolysis and hemolytic anemia.Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]).Monitor blood pressure prior to, during, and following PANZYGA infusion.Carefully consider the relative risks and benefits before prescribing the high dose regimen (for cITP) in patients at increased risk of volume overload.PANZYGA is made from human plasma and may contain infectious agents, e.g. viruses and theoretically, the Creutzfeldt-Jakob disease agent.Adverse Reactions
PI – The most common adverse reactions (>5% study subjects) were headache, nausea, fever, fatigue, and abdominal pain.
cITP in adults – The most common adverse reactions (>5% study subjects) were headache, fever, nausea, vomiting, dizziness, and anemia.CIDP in adults – The most common adverse reactions (>5% study subjects) were headache, fever, dermatitis, and blood pressure increase.The risk information provided here is not comprehensive; see full Prescribing Information and Boxed Warning for PANZYGA. You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088. PANZYGA® is a registered trademark of Octapharma AG. Please click here for full Prescribing Information, including BOXED WARNING.

Manufactured by Octapharma Pharmazeutika Produktionsges m.b.H.
Distributed by Pfizer Labs, Division of Pfizer Inc.
INDICATIONS
PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.